Graham Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Graham Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-417,161	Closed	-$2.07M	–	1393
2024 Q2	$1.07M	Buy	+417,161	New	+$1.42M	0.02%	401
2023 Q4	–	Sell	-10,612	Closed	-$122K	–	1398
2023 Q3	$122K	Sell	10,612 -21,685	-67%	-$417K	﹤0.01%	923
2023 Q2	$817K	Buy	+32,297	New	+$1.01M	0.02%	417
2022 Q2	–	Sell	-20,030	Closed	-$390K	–	1289
2022 Q1	$390K	Buy	+20,030	New	+$304K	0.01%	642

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Graham Capital Management's RVNC Position: Q3 2024 in Review

Graham Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 417,161 shares — an estimated $2.07M sold.

Graham Capital Management first reported a position in RVNC in Q1 2022 and held it in 4 quarters. The position peaked at $1.07M in Q2 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Graham Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Graham Capital Management sold 417,161 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $2.07M.
Graham Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 4 quarters.
Graham Capital Management's Revance Therapeutics, Inc. position peaked at $1.07M in Q2 2024.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.